A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.
Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of subjects remained VZV-antibody positive and 60% had VZV-specific cell-mediated immunity. No child developed herpes zoster.
Gershon
Anne A
AA
Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. aag1@columbia.edu
Levin
Myron J
MJ
Weinberg
Adriana
A
Song
Lin-Yee
LY
LaRussa
Philip S
PS
Steinberg
Sharon P
SP
Bartlett
Patterson
P
D000914:Antibodies, Viral / Q000097:blood; D019433:Chickenpox Vaccine / Q000009:adverse effects* / Q000276:immunology*; D002648:Child; D015658:HIV Infections / Q000276:immunology*; D006562:Herpes Zoster / Q000517:prevention & control*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D008137:Longitudinal Studies; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D014613:Vaccines, Attenuated